Stay updated on Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.

Latest updates to the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page
- Check2 days agoChange DetectedRevision v3.5.4 was added to the study's record, replacing the previous v3.5.3. This signals a new version of the page, likely reflecting minor updates to the study record or its metadata rather than a substantive change to study content.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page's revision tag updated to v3.5.3, replacing the previous v3.5.2. This indicates an update to the page version rather than changes to the study data or visible content.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedRevision updated to v3.5.2, replacing the previous v3.5.0.SummaryDifference0.0%

- Check59 days agoChange DetectedRevision updated to v3.5.0. The previous revision v3.4.3 was removed.SummaryDifference0.0%

- Check66 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check94 days agoChange DetectedStudy status updated to Completed with 137 participants enrolled and a completion date of 2026-01-28, with the record revision to v3.4.2. The previous funding notice and the 'Active, not recruiting' indicator were removed.SummaryDifference0.7%

Stay in the know with updates to Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.